Healthcare Industry News: Ardea Biosciences
News Release - April 9, 2013
Zosano Pharma, Inc. Announces Key Strategic HireSeasoned Business Development Executive Chris Krueger Joins as Chief Business Officer
FREMONT, Calif., April 9, 2013 -- (Healthcare Sales & Marketing Network) -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business development, legal, and investor relations activities.
"We are delighted to have Chris join our team. He brings extremely valuable and relevant healthcare industry experience to Zosano Pharma. His business development expertise and a track record of building successful businesses will be invaluable as we prepare to advance several of our drug candidates," commented Vikram Lamba, Zosano Chief Executive Officer.
Prior to joining Zosano Pharma, Mr. Krueger served as Senior Vice President and Chief Business Officer at Ardea Biosciences. In addition to several successful financings at Ardea, he completed a $407 million global partnership with Bayer HealthCare. Previously, Mr. Krueger served in senior executive roles at Protemix, Xencor, X-Ceptor Therapeutics and Aurora Biosciences. In his previous roles, he completed a broad range of transactions, including licensing, strategic alliances, mergers and acquisitions and equity and debt financings. Earlier in his career, Mr. Krueger was a corporate lawyer at Cooley LLP.
"It's exciting for me to join the Zosano team as the company enters its next stage of corporate growth," said Mr. Krueger. "With its novel transdermal drug delivery system, Zosano is poised to develop therapeutic products through its own efforts and through strategic collaborations."
About Zosano Pharma
Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle-free, and pain-free system. Zosano is a fully integrated development company with its own cGMP manufacturing facility. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.
Source: Zosano Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.